CN Patent

CN114105976B — 选择性rock2激酶抑制剂

Assigned to Hangzhou Bangshun Pharmaceutical Co Ltd · Expires 2024-04-26 · 2y expired

What this patent protects

本发明涉及一种通式(I)所示的ROCK2激酶抑制剂及其在制备预防和/或治疗与ROCK2相关障碍的疾病的药物中的用途。本发明的化合物是理想的高效选择性ROCK2激酶抑制剂，可用于治疗和/或预防肺纤维化、肝纤维化、肾纤维化、心脏纤维化或非酒精性脂肪性肝炎等疾病。

USPTO Abstract

本发明涉及一种通式(I)所示的ROCK2激酶抑制剂及其在制备预防和/或治疗与ROCK2相关障碍的疾病的药物中的用途。本发明的化合物是理想的高效选择性ROCK2激酶抑制剂，可用于治疗和/或预防肺纤维化、肝纤维化、肾纤维化、心脏纤维化或非酒精性脂肪性肝炎等疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN114105976B
Jurisdiction
CN
Classification
—
Expires
2024-04-26
Drug substance claim
No
Drug product claim
No
Assignee
Hangzhou Bangshun Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.